Clinical Trial Update: ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of ISIS 2503 for metastatic or locally recurrent colorectal cancer has been terminated; University of Alabama at Birmingham sponsored the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ISIS 2503 (ISIS-2503)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED